H1 profit well ahead of market expectations and confirmation of the successful sale of Biolink are fitting endorsements of Blue Cap’s investment strategy. Indeed, more of the same appears on the cards with full-year management guidance of strong momentum, notably in the turnaround of Neschen, as well as new investment opportunities, which the now de-geared company is well-placed to seize. Despite a buoyant share price (up over 50% since our positive initiation report in July), the ratin
16 Oct 2017
In full swing
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
In full swing
Blue Cap AG (B7E:ETR) | 0 0 1.5% | Mkt Cap: 66.1m
- Published:
16 Oct 2017 -
Author:
Richard Finch -
Pages:
4
H1 profit well ahead of market expectations and confirmation of the successful sale of Biolink are fitting endorsements of Blue Cap’s investment strategy. Indeed, more of the same appears on the cards with full-year management guidance of strong momentum, notably in the turnaround of Neschen, as well as new investment opportunities, which the now de-geared company is well-placed to seize. Despite a buoyant share price (up over 50% since our positive initiation report in July), the ratin